Skip to content

Effect of Perioperative Dual Orexin Receptor Antagonist Use on Postoperative Delirium in Geriatric Surgical Patients

Effect of Perioperative Dual Orexin Receptor Antagonist Use on Postoperative Delirium in Geriatric Surgical Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123102
Enrollment
Unknown
Registered
2026-04-21
Start date
2026-04-30
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Delirium

Interventions

DORA Group:From 1 day before surgery to the 3rd day after surgery, for a continuous 4 days, take Relebresen 5mg 1 hour before bedtime each night.
Placebo group:From 1 day before surgery to the 3rd day after surgery, for a total of 4 consecutive days, take 1 placebo pill 1 hour before bedtime each night.

Sponsors

Rui'an City People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1.Age >= 65 years 2.No delirium at baseline as assessed by DSM-5 diagnostic criteria for delirium 3.ASA Physical Status Classification I–III 4.Elective surgery 5.Capable of cooperating with cognitive-delirium assessment preoperatively; with intact vision, hearing, and speech 6.Signed informed consent by the patient or legally authorized representative prior to enrollment

Exclusion criteria

Exclusion criteria: 1.Previous identical surgery 2.AUDIT-C score indicating high risk for alcohol withdrawal delirium 3.History of confirmed psychiatric disorders, epilepsy, or other active neurological diseases 4.Contraindications to dual orexin receptor antagonists 5.Inability to complete treatment, assessments, or other examinations for any reason 6.Currently participating in other clinical trials, or any condition judged by the investigator as interfering with this study 7.Any other condition deemed by the investigator as unsuitable for participation in this study

Design outcomes

Primary

MeasureTime frame
DSM-5, Delirium Diagnostic Assessment;

Secondary

MeasureTime frame
2014CAM-S;

Countries

China

Contacts

Public ContactHuang Xuerong

Rui'an City People's Hospital

hxr02@126.com+86 139 5886 0081

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026